Cases
MiMedx Group, Inc. (NASDAQ: MDXG)
Securities Class Action
Overview
Overview
- Date:
- 6/22/2018
- Company Name:
- MiMedx Group, Inc.
- Stock Symbol:
- MDXG
- Status:
- Closed/Complete
NEW YORK, June 22, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG). Our investigation focuses on whether MiMedx's officers and/or directors breached their fiduciary duties to MiMedx's shareholders or otherwise violated state or federal laws.
In April 2018, investors in MiMedx brought a class action complaint against the Company in federal court, alleging that between March 7, 2013 and February 21, 2018, MiMedx was engaged in a "channel-stuffing" scheme designed to inappropriately recognize revenue that had not yet been realized and that the Company lacked adequate internal controls over financial reporting.
Then, on June 7, 2018, MiMedx announced that it would restate its financial statements for the fiscal years of 2012, 2013, 2014, 2015, and 2016, along with its interim financial statements released in March, June, and September 2017. The Company also disclosed that all financial information for the fourth quarter of 2017 and first quarter of 2018 could not be relied upon. MiMedx also withdrew its projections for fiscal year 2018. As part of its announcement, MiMedx disclosed that its Chief Financial Officer and Corporate Controller left those roles on June 6, 2018, and that its Chief Accounting Officer position remained unfilled.
If you are a shareholder of MiMedx, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
In April 2018, investors in MiMedx brought a class action complaint against the Company in federal court, alleging that between March 7, 2013 and February 21, 2018, MiMedx was engaged in a "channel-stuffing" scheme designed to inappropriately recognize revenue that had not yet been realized and that the Company lacked adequate internal controls over financial reporting.
Then, on June 7, 2018, MiMedx announced that it would restate its financial statements for the fiscal years of 2012, 2013, 2014, 2015, and 2016, along with its interim financial statements released in March, June, and September 2017. The Company also disclosed that all financial information for the fourth quarter of 2017 and first quarter of 2018 could not be relied upon. MiMedx also withdrew its projections for fiscal year 2018. As part of its announcement, MiMedx disclosed that its Chief Financial Officer and Corporate Controller left those roles on June 6, 2018, and that its Chief Accounting Officer position remained unfilled.
If you are a shareholder of MiMedx, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.